FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Review Period Set for Biomimics Vascular Stent

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Veryan Medicals Biomimics 3D Vascular Stent Sys...

Special Counsel Troubled by FDA Response to Whistleblower

Special Counsel Henry Kerner says he is troubled by the way FDA handled a whistleblower complaint involving inspections at biologic facilities.

Medical Devices

Accelerate Sustainable Capability Pilot Volunteers Sought

FDA provides information for applying to participate in the Medical Device Innovation Consortium Accelerate Sustainable Capability pilot study.

Federal Register

Editorial Changes Made Due to Obsolete FDA Office

Federal Register notice: FDA amends its medical device regulations to make an editorial nonsubstantive change and replace a reference to an obsolete o...

Federal Register

Panel to Discuss BLA for Type 1 Diabetes

Federal Register notice: FDA announces a 5/27 Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss a Provention Bio BLA for eplizu...

Federal Register

2-Day FDA Science Forum in May

Federal Register notice: FDA announces a 5/26-27 workshop entitled FDA Science Forum 2021.

Federal Register

Technical Corrections for Drug Import Entries

Federal Register notice: FDA amends its electronic import entries regulation to correct the statutory citation in the sections of that regulation requ...

Medical Devices

CDRH Medical Device Development Tools Help Developers: Shuren

CDRH director Jeffrey Shuren describes the Centers Medical Device Development Tools program and Catalog of Regulatory Science Tools.

Human Drugs

Advisory Committee Aducanumab Deliberations Explained

Three university experts say their advisory committee experience with Biogens aducanumab shows the value in randomized clinical trials that patients a...

Human Drugs

Higher Risk of Arrhythmias in Some Patients on Lamictal: FDA

FDA says studies found an increased risk of heart arrhythmias in patients with heart disease who take GlaxoSmithKlines Lamictal or a generic.